MOESM1 of Liraglutide suppresses non-esterified free fatty acids and soluble vascular cell adhesion molecule-1 compared with metformin in patients with recent-onset type 2 diabetes

Additional file 1: Table S1. Changes of plasma lipids and lipoprotein metabolism parameters before and after 8-week treatment with liraglutide and metfotmin. Table S2. Comparisons of body weight, plasma glucose and insulin secretion capacity before and after 8-week treatment between two groups. Table S3. Comparisons of sVCAM-1,sICAM-1,PAI-1 levels before and after 8-week treatment between two groups. Table S4. Spearman rank correlations in ΔNEFA with ΔsVCAM-1, ΔAUCins and ΔI30/ΔG30 after 8-week treatment.

补充材料1：表S1。利拉鲁肽与二甲双胍（metformin）治疗8周前后血浆脂质及脂蛋白代谢参数的变化。表S2。两组接受8周治疗前后体质量、血浆葡萄糖及胰岛素分泌功能的比较。表S3。两组接受8周治疗前后可溶性血管细胞黏附分子-1（sVCAM-1）、可溶性细胞间黏附分子-1（sICAM-1）及纤溶酶原激活物抑制剂-1（PAI-1）水平的比较。表S4。8周治疗后非酯化脂肪酸（NEFA）变化量（ΔNEFA）与可溶性血管细胞黏附分子-1变化量（ΔsVCAM-1）、胰岛素曲线下面积变化量（ΔAUCins）及ΔI30/ΔG30的斯皮尔曼等级相关分析。